Trial Profile
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Soquelitinib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma; T-cell leukaemia; T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors Corvus Pharmaceuticals
- 19 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2023 Results (n=3) assessing prognostic biomarkers analysis to study immune regulatory mechanisms ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 09 Dec 2023 According to a Corvus Pharmaceuticals media release, a total of 36 patients were enrolled in the Phase 1/1b trial at the optimum 200 mg two-times a day dose, including 21 evaluable patients who would be eligible in the planned registrational Phase 3 clinical trial based on more than 1 and less than 3 prior therapies